## CDNA: CareDx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.9% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. CDNA: Wells Fargo Raises Price Target to $18, Maintains Equal-We**
- Source: GuruFocus | 20251216T021020 | Somewhat-Bullish | Relevance: 100%
- Wells Fargo analyst Brandon Couillard has increased the price target for CareDx (CDNA) to $18.00 from $14.00, while maintaining an "Equal-Weight" rating. Despite this upgrade, GuruFocus estimates suggest a potential downside for CDNA, with an estimated fair value of $18.08, indicating an 8.87% decrease from its current price. CareDx operates as a precision medicine company specializing in healthcare solutions for transplant patients, with services like AlloSure Kidney and AlloMap Heart.

**2. CareDx price target raised to $18 from $14 at Wells Fargo**
- Source: TipRanks | 20251216T021020 | Bullish | Relevance: 100%
- Wells Fargo analyst Brandon Couillard increased the price target for CareDx (CDNA) to $18 from $14, while maintaining an Equal Weight rating. This adjustment reflects lifting U.S. policy uncertainty on Pharma and robust forward growth expectations, which suggests potential upside for the company. The firm notes a favorable setup for "Tools" in this environment.

**3. Transplantation Market to Reach US$ 31.92 Billion by 2032 at 8.6%**
- Source: openPR.com | 20251216T101020 | Somewhat-Bullish | Relevance: 92%
- The global transplantation market is projected to grow from US$ 16.48 billion in 2024 to US$ 31.92 billion by 2032, exhibiting an 8.6% CAGR. This growth is driven by the increasing prevalence of organ failure, advancements in surgical techniques, and rising awareness of organ donation. North America currently leads the market with a 39% share, with key players including Abbott, Novartis, and CareDx.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $18 | $14 | +29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 4 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Blackrock Inc.: 9.3% (+2.3%)
- Vanguard Group Inc: 7.3% (-23.6%)
- BAMCO Inc.: 6.1% (+29.5%)
- State Street Corpora: 5.0% (+17.7%)
- Ophir Asset Manageme: 4.3% (+16.1%)

### Key Risks

1. High beta (2.54) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.1%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 22.3x attractive for 27% earnings growth. Quality metrics strong (ROE 24%, margin 20%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.39). Analyst sentiment positive (1 raises, avg +29%). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.0B |
| Beta | 2.54 |
| 52W Range | $10.96 - $25.95 |
| Short Interest | 13.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.12 |
| Forward P/E | 22.3 |
| Current P/E | 28.3 |
| YoY Growth | 26.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 5.6% to 2.9% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.1pp (needs >3.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.94% (CS: 57) | Neutral |
| RSI_14 | 61.2 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 1.057x | Above |
| vs SMA50 | 1.185x | Above |
| vs SMA200 | 1.193x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.49
- **Stop Loss:** $17.75 (8.9% risk)
- **Target:** $21.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 620
- **Position Value:** $12,083.80
- **Portfolio %:** 12.08%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-03-02 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.14 | $0.28 | +97.6% |
| 2025Q2 | $0.12 | $0.10 | -18.0% |
| 2025Q1 | $0.07 | $0.10 | +46.4% |
| 2024Q4 | $0.15 | $0.18 | +22.0% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*